54777-65-0

Usage

InChI:InChI=1/C9H10ClNO/c1-7(12)11-9-4-2-8(6-10)3-5-9/h2-5H,6H2,1H3,(H,11,12)

Upstream product

• 542-88-1 bis(2-chloromethyl)ether 
• 103-84-4 Acetanilid 
• 16375-88-5 N-(4-hydroxymethylphenyl)acetamide 
• 75-44-5 phosgene 
• 67-66-3 chloroform 
• 7509-68-4 N-(4-(piperidin-1-ylmethyl)phenyl)acetamide 
• 108-88-3 toluene 
• 124-63-0 methanesulfonyl chloride 
• 623-04-1 4-aminobenzenemethanol 
• 7782-50-5 chlorine 
• 113149-80-7 4-acetamidobenzyl Co(III)(dmgH)2py 

Downstream Products

• 122-85-0 para-acetamidobenzaldehyde 
• 103-89-9 4-Methylacetanilide 
• 246237-05-8 N-[4-(2-oxopropoxymethyl)phenyl]acetamide 
• 246237-22-9 N-[4-(2-hydroxy-2-methylpent-4-enyloxymethyl)phenyl]acetamide 
• 246237-13-8 (R)-N-[4-(2-hydroxy-2-methyl-4-oxobutoxymethyl)phenyl]acetamide 
• 246236-99-7 N-[4-((E)-(R)-2-Hydroxy-2-methyl-6-oxo-hept-4-enyloxymethyl)-phenyl]-acetamide 
• 152595-67-0 1,2-Dihydro-4-[(4-ethylaminophenyl)methyl]-5-(trifluoromethyl)-3H-pyrazol-3-one 
• 52377-76-1 N-[4-((9H-purin-6-ylthio)methyl)phenyl]acetamide 
• 144871-84-1 diethyl methyl-(4-benzylamino)benzylmalonate 
• 144871-85-2 Methyl-(4-benzylamino)benzylmalonic acid 
• 144872-10-6 diethyl 2-(4-aminobenzyl)-2-methylmalonate 
• 144871-86-3 2-methyl-3-(4-benzylamino)phenyl propionic acid 

Relevant academic research and scientific papers

Cellular protection of SNAP-25 against botulinum neurotoxin/A: Inhibition of thioredoxin reductase through a suicide substrate mechanism

Botulium neurotoxins (BoNTs) are among the most lethal toxins known to man. They are comprised of seven serotypes with BoNT/A being the most deadly; yet, there is no approved therapeutic for their intoxication or one that has even advanced to clinical trials. Botulinum neurotoxicity is ultimately governed through light chain (LC) protease SNARE protein cleavage leading to a loss of neurotransmitter release. Pharmacological attempts to ablate BoNT/A intoxication have sought to either nullify cellular toxin entry or critical biochemical junctions found within its intricate mechanism of action. In these regards, reports have surfaced of nonpeptidic small molecule inhibitors, but few have demonstrated efficacy in neutralizing cellular toxicity, a key prerequisite before rodent lethality studies can be initiated. On the basis of a lead discovered in our BoNT/A cellular assay campaign, we investigated a family of N-hydroxysuccinimide inhibitors grounded upon structure activity relationship (SAR) fundamentals. Molecules stemming from this SAR exercise were theorized to be protease inhibitors. However, this proposition was overturned on the basis of extensive kinetic analysis. Unexpectedly, inhibitor data pointed to thioredoxin reductase (TrxR), an essential component required for BoNT protease translocation. Also unforeseen was the inhibitors' mechanism of action against TrxR, which was found to be brokered through a suicide-mechanism utilizing quinone methide as the inactivating element. This new series of TrxR inhibitors provides an alternative means to negate the etiological agent responsible for BoNT intoxication, the LC protease.

PYRIMIDINE-5-CARBOXAMIDE COMPOUNDS, PROCESS FOR PRODUCING THE SAME AND USE THEREOF

A compound of the formula wherein R1 is a heterocycle having a skeleton consisting of 3 to 15 atoms including 1 to 5 nitrogen atom(s), which heterocycle is attached by a secondary nitrogen atom constituting the heterocycle; X is an oxygen atom, a nitrogen atom optionally substituted by a hydrocarbon group having 1 to 5 carbon atom(s) or a sulfur atom optionally oxidized with 1 or 2 oxygen, Y is a bond or a C1-5 alkylene group, R2 is (1) a hydrogen atom, (2) a hydroxy group, (3) a C1-5 alkoxy group, (4) a C1-5 alkylthio group, (5) a carbocycle having 3 to 15 carbon atoms or (6) a heterocycle having a skeleton consisting of 3 to 15 atoms including 1 to 5 heteroatom(s), provided that when Y is a bond, R2 is a carbocycle having 3 to 15 carbon atoms or a heterocycle having a skeleton consisting of 3 to 15 atoms including 1 to 5 heteroatom(s) and; one of R3 and R4 is a hydrogen atom or a group of the formula: -Z-R5 (Z is a bond or C1-10 alkylene group optionally having substituent(s) and R5 is (1) a hydrogen atom, (2) a hydroxy group, (3) a C1-5 alkoxy group, (4) a nitrile group, (5) a C1-5 alkoxy-carbonyl group, (6) a carboxyl group, (7) a carbamoyl group, (8) a (mono or di-C1-5 alkyl)carbamoyl group, (9) an amino group, (10) a (di or mono-C1-5 alkyl)amino group, (11) a (C1-5 alkoxy-carbonyl)amino group, (12) a C1-5 alkylthio group, (13) a carbocycle having 3 to 15 carbon atoms or (14) a heterocycle having a skeleton consisting of 3 to 15 atoms including 1 to 5 heteroatom(s)); the other is a group of the formula: -Z-R5 (Z and R5 are as defined above); and R3 and R4 may form, together with the adjacent nitrogen atom, a heterocycle having a skeleton consisting of 3 to 15 atoms, which heterocycle is attached by a secondary nitrogen atom constituting the heterocycle, wherein the above-mentioned heterocycle and a carbocycle having 3 to 15 carbon atoms are each optionally substituted by substituent(s) selected from the group consisting of C1-8 alkyl, C2-8 alkenyl, C2-8 alkynyl, C7-16 aralkyl, C3-8 cycloalkyl, C3-8 cycloalkenyl, C6-14 aryl, C1-8 alkoxy, C1-3 alkylenedioxy, hydroxy, halogen atom, amino, (di or mono-C1-5 alkyl)amino, (C1-5 alkoxy-carbonyl)amino, (C1-5 acyl)amino, (C1-5 acyl) (C1-5 alkyl)amino, C1-5 alkylthio, nitrile, nitro, C1-5 alkoxy-carbonyl, carboxyl, C1-5 alkyl-carbonyloxy, oxo, thioxo, C1-6 acyl group, sulfamoyl and (di or mono-C1-5 alkyl)sulfamoyl, or a salt thereof or a prodrug thereof have a superior cGMP specific phosphodiesterase (PDE) inhibitory activity, and can be used as an agent for the prophylaxis or treatment of cardiovascular diseases such as angina pectoris, heart failure, cardiac infarction, hypertension, arteriosclerosis and the like, allergic diseases such as asthma, or disorders of male or female genital function and the like.

Halogenation of benzyl- and (heteroaromatic methyl)cobaloximes: Direct competition between ring halogenation and cobalt-carbon bond cleavage

(4-Acetamidobenzyl)- and (4-(dimethylamino)benzyl)cobaloximes react rapidly with low concentrations of chlorine and bromine in acetic acid or chloroform at room temperature under nitrogen. Both ring-halogenated organometallic products and direct Co-C cleavage products are formed. However, (4-methoxybenzyl)cobaloxime forms 4-methoxy-2-halotoluene as the exclusive product. (3-Methylbenzyl)cobaloxime undergoes a substantial proportion of ring substitution by both Br2 and Cl2 in competition with the cleavage of the Co-C bond. (3-Methoxybenzyl)cobaloxime forms only the ring-substituted organometallic product. A remarkable difference in reactivity between 2- and 3-isomers of the (thienylmethyl)- and (furylmethyl)cobaloximes is observed; for example, Co-C cleavage is the primary process in furfuryl- and (2-thienylmethyl)cobaloximes whereas ring halogenation occurs much faster in the 3-isomer. The results are discussed in terms of a σ-π delocalization phenomenon by which the electronic effect of a substituent in the benzyl group is effectively transmitted to the Co-C bond reactivity. The substituent effect of the metallomethyl group -CH2Co(dmgH)2py is found to be more than that of the methoxy group. The mechanism of the Co-C cleavage is described.

Halogenolysis of Benzylcobaloximes

The reaction of substituted benzylcobaloximes p-RC6H4Co(dmgH)2-Py (R=OMe, NHCOCH3 and NMe2) and m-RC6H4CH2Co(dmgH)2Py (R=Me, OMe) with halogens (Cl2 and Br2) in chloroform under nitrogen forms ring substituted organic and organometallic products.